Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study
Brexpiprazole treatment for 10 weeks improved agitation in Alzheimer's dementia. The efficacy of brexpiprazole 1 mg/day has been confirmed for the first time. The incidence of adverse events was higher compared to the previous studies. Both brexpiprazole 1 mg/day and 2 mg/day were generally well tolerated.
Authors
- Katsuhiro Iba (ORCID: https://orcid.org/0000-0003-1521-9067)
- Naoki Hirota (ORCID: https://orcid.org/0009-0002-9634-2488)
- Jun Adachi (ORCID: https://orcid.org/0000-0003-1220-3246)
- Masami Nakai (ORCID: https://orcid.org/0000-0001-5159-0432)
- Kaneyoshi Takahashi (ORCID: https://orcid.org/0009-0009-1858-1150)
- Yu Nakamura (ORCID: https://orcid.org/0000-0003-2866-3669)
- Naoki Mori (ORCID: https://orcid.org/0000-0003-3998-6711)
- Koichi Shimizu (ORCID: https://orcid.org/0009-0008-6704-6966)
Institutions
- Otsuka (Japan) (JP)
- Kagawa University (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1002/alz.14282
- Citations
- 24
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.25
Funders
- Otsuka Pharmaceutical